Skip to main content

Table 1 Characteristics of selected cohort and relationship with endocrine initiation and adherence

From: Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65

  Initiation    Adherence   
  Selected cohort Selected cohort
  Number Row % P Number Row % P
Total 5014 84   4218 61  
Recurrence score    <0.0001    0.13
 Low (<18) 821 91   745 64  
 Intermediate (18–30) 621 91   566 63  
 High (>30) 165 83   137 66  
 No oncotype 3407 81   2770 60  
Year diagnosed    0.06    0.001
 2006–2007 1929 85   1639 58  
 2008–2009 2097 83   1734 63  
 2010 988 86   845 65  
Age at diagnosis, years    0.14    <0.001
 24–39 361 81   293 51  
 40–49 1621 83   1350 60  
 50–59 2091 85   1784 63  
 60–63 941 84   791 64  
Race-ethnicity    0.10    0.004
 NH white 4263 84   3593 62  
 NH black 188 79   148 49  
 Hispanic 205 82   168 58  
 Other/unknown 358 86   309 66  
Marital status    0.03    0.002
 Not married 1427 82   1177 57  
 Married 3507 85   2978 63  
 Missing 80 79   63 63  
Prior cancer    0.77    0.24
 No 4766 84   4011 61  
 Yes 248 83   207 61  
State    0.04    0.14
 CA 1985 83   1642 61  
 GA 930 83   771 58  
 KY 483 87   421 62  
 NY 771 86   662 65  
 OH 845 85   722 62  
Area    0.76    0.15
 Rural 254 83   212 57  
 Urban 4703 84   3959 62  
 Missing 57 82   47 62  
Median household income    0.23    0.03
 1 (lowest) 952    802 60  
 2 921 84   766 61  
 3 1071 83   892 58  
 4 999 83   864 62  
 5 (highest) 1014 86   847 66  
 Missing 57 84   47 62  
Stage    0.001    0.44
 I 3035 83   2504 61  
 II 1979 87   1714 62  
Nodal involvement    0.001    0.50
 N0 3767 83   3122 61  
 N1mic 325 87   292 61  
 N1 922 90   804 63  
HER2 status    0.66    0.35
 Negative 2283 84   1928 62  
 Borderline 55 87   48 52  
 Unknown 2676 84   2242 61  
Hormone receptor status    <0.001    0.89
 Both ER and PR positive 4299 85   3664 61  
 Only ER or PR positive 715 77   554 61  
Histological grade    0.04    0.17
 1–2 3737 85   3175 62  
 3 1076 82   887 59  
 Missing 201 78   156 58  
One-year comorbidities    0.17    0.08
 0 4395 84   3709 62  
 1 or more 619 82   509 58  
Surgery type    0.16    0.45
 Breast-conserving surgery 3049 84   2569 62  
 Mastectomy 1956 85   1642 61  
 Unknown/missing 9 78   7 71  
Endocrine therapy       <0.001
 Tamoxifen only --    1512 58  
 AIs only --    1930 65  
 Tamoxifen and AIs --    776 58  
Adjuvant chemotherapy    <0.001    0.86
 No 2585    2084 61  
 Yes 2429    2134 61  
  1. Nodal involvement: N0 no cancer in the lymph nodes; N1mic lymph node cancer that can only be seen under a microscope (<2 mm in size); N1 cancer at least 2 mm in size in at least one of three axillary lymph nodes. NH non-Hispanic, HER2 human epidermal growth factor receptor 2, ER estrogen receptor, PR progesterone receptor, AI aromatase inhibitor